Promotional pricing lifted test volume sharply, but margins fell and losses widened.
GRAL GRAIL, Inc. Common Stock
XNAS
131.93
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GRAL
$131.93
—
What changed
Recent filings, trades and movesKey stats
$131.93
- 52-Week Range
- $41.50 – $166.47
- YTD
- +48.45%
- IV Rank (30D)
- 19.74
- Straddle Price
- $26.90
- P/C Vol Ratio
- 0.52
- Market Cap
- $5.5B
- Open
- $123.63
- Day Range
- $122.36 – $134.26
- Volume
- 407,184
- Prev Close
- $121.44
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.99 |
| Cost of Equity (CAPM) | 14.37% (VRP-adj) |
| WACC | 14.67% |
| Volatility Risk Premium | -20.9pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +23.5% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.3B |
| Return on Equity (TTM) | -15.4% |
| Book / Price | 48.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 49.7% |
| FCF Margin (TTM) | -179.2% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $116.60 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $135.91 |
| Bollinger Width / SMA20 | 33.8% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $5B |
Peers used for multiples: BLLN, CAI, CDNA, CELC, DGX, EXAS, GH, LH, NTRA, RDNT
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
99%
20-Day Fair Value
≈ by Dec 8, 2026
$133.59
α +2.2%
rank 68%
conviction
94%
40-Day Fair Value
≈ by Jan 6, 2027
$136.08
α +4.1%
rank 69%
conviction
91%
60-Day Fair Value
≈ by Feb 4, 2027
$142.28
α +8.8%
rank 72%
conviction
99%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 31.2× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 44.3× · 7 peers |
| Peer P/B | $498.95 | 12% | median 8.5× · 8 peers |
| Peer P/S | $30.02 | 12% | median 7.1× · 9 peers |
| Market Anchor (SMA50) | $116.60 | 47% | stability 80% (BB-width) |
| Options Expected (B-L 30d) | $119.28 | 30% | 30 strikes · skew +0.18 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- SERVICES-MEDICAL LABORATORIES (8071) · industry map
- Exchange
- XNAS
- Market Cap
- $5.5B
- Employees
- 910
- List Date
- 2024-06-12
- CIK
- 0001699031
- Last Earnings
- Nov 4 after close · −17.1% vs ±18.2% expected
- Next Earnings
- ~Feb 18, 2027 (estimated)
- Headquarters
- Sunnyvale, CA
- Homepage
- https://www.grail.com
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | 68.97% | 10.07% | 39.52% |
| Feb | -- | 33.70% | -48.65% | -7.47% |
| Mar | -- | -29.70% | -1.81% | -15.75% |
| Apr | -- | 37.43% | 1.64% | 19.54% |
| May | -- | 18.22% | 32.59% | 25.41% |
| Jun | -9.59% | 37.12% | 6.01% | 11.18% |
| Jul | 2.81% | -30.51% | -0.54% | -9.41% |
| Aug | -15.20% | 0.00% | 12.95% | -0.75% |
| Sep | 3.77% | 87.06% | 75.61% | 55.48% |
| Oct | 2.42% | 48.13% | 8.20% | 19.58% |
| Nov | 29.15% | 22.92% | -2.64%* | 16.48% |
| Dec | -4.70% | -12.90% | -- | -8.80% |
| Total | 3.11% | 629.38% | 64.77% | 232.42% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $135.58
SMA 50: $117.57
SMA 200: $78.90
Current: $130.76
EMA 12: $134.33
EMA 26: $131.45
MACD: 2.8743 | Signal: -3.3033
BULLISH
ADX (14): 34.01
TREND
+DI: 21.61
−DI: 23.93
Momentum Oscillators
RSI (14): 49.86
NEUTRAL
Stoch %K: 14.94
Stoch %D: 25.76
Williams %R: -69.35
Volume & Volatility
BB Upper: $158.66
BB Lower: $112.50
NEUTRAL
OBV: 5,957,395
Vol SMA 20: 942,038
Vol ROC: -54.49%
ATR: $12.30
True Range: $12.82
HV 20: 114.9%
HV 30: 107.9%
HV 60: 104.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-07T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before GRAL’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
SYMBOL: GRAL
Executive Summary Overall Assessment: BEARISH with confidence level (8/10)
Key Drivers:
- Technical indicators suggest a potential breakdown from the SMA 200
- Recent news headlines have been negative, fueling bearish sentiment
- High volatility and beta indicate increased risk
Primary Risks:
- Technical breakdown from the SMA 200 could lead to significant losses
- Negative news sentiment may continue to drive prices lower
- High volatility increases the potential for unexpected moves
Investment Thesis: GRAIL (GRAL) appears poised for a technical breakdown, driven by negative news sentiment and high volatility. While there are some positive signs in recent news headlines, the overall bearish trend is likely to continue.
Recent News Sentiment Impact: The negative news headlines have had a significant impact on sentiment, driving prices lower and increasing risk. The market narrative is focused on potential regulatory issues and lawsuits, which may not be fully priced in yet.
Technical Analysis Trend Direction:
- Short-term: Neutral
- Medium-term: Bearish
- Long-term: Neutral
Support/Resistance Levels: The SMA 200 provides key resistance at $73.59, while the SMA 50 offers support at $67.56.
Momentum Signals:
- RSI interpretation: Neutral (51.83)
- MACD signal: Bullish momentum continues with a bullish crossover
- Bollinger Bands position: Neutral (squeeze)
Volume Analysis: The volume trends suggest institutional interest is increasing, but it may not be enough to offset the bearish momentum.
News & Sentiment Analysis Recent Headlines Summary: Negative news headlines have dominated recent market activity, focusing on potential regulatory issues and lawsuits.
Sentiment Assessment: Aggregate news sentiment is NEGATIVE (6/10)
Catalyst Identification: The upcoming earnings release could provide a catalyst for further price movement. However, the negative news sentiment may continue to drive prices lower.
Market Narrative: The market narrative is focused on potential regulatory issues and lawsuits, which may not be fully priced in yet.
Risk & Volatility Assessment Beta Interpretation: High risk (beta >1.5)
Volatility Regime: Current volatility levels are higher than historical norms.
Options Market Signals:
- IV rank: Low (3.8%)
- Put/call ratio: Bearish (1.86)
- Unusual activity: Increased put buying
Downside Protection: The SMA 50 and SMA 200 provide support, but the market may need to test these levels before stabilizing.
Market Context & Positioning Sector Performance: GRAIL is underperforming its sector peers.
Institutional Activity: Increased institutional interest may not be enough to offset the bearish momentum.
Correlation Analysis: The stock has a high correlation with the market, indicating that it may follow broader market trends.
Relative Valuation: GRAIL appears undervalued relative to its trading range.
Key Levels & Action Items Critical Price Levels:
- Support: SMA 50 ($67.56), SMA 200 ($73.59)
- Resistance: Upper Bollinger Band ($76.38)
Breakout/Breakdown Levels: The SMA 200 provides key resistance, while the SMA 50 offers support.
Time-Sensitive Catalysts: The upcoming earnings release could provide a catalyst for further price movement.
Risk Management: Stop-loss levels should be set at the SMA 50, and position sizing considerations should prioritize risk management.
Conclusion GRAIL (GRAL) appears poised for a technical breakdown, driven by negative news sentiment and high volatility. While there are some positive signs in recent news headlines, the overall bearish trend is likely to continue. Investors should prioritize risk management and consider setting stop-loss levels at the SMA 50.
Generated
News
All GRAL news →
Earnings History
7 of 10 under expected move
Avg Expected Move
12.95%
Avg Actual Move
14.10%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-13 | After-Close | 14.52% | 2.84% | 0.20x | Within |
| 2024-11-12 | After-Close | 9.48% | 5.50% | 0.58x | Within |
| 2025-01-15 | After-Close | 9.10% | 1.00% | 0.11x | Within |
| 2025-05-13 | After-Close | 16.44% | 23.32% | 1.42x | Exceeded |
| 2025-08-12 | After-Close | 15.62% | 1.13% | 0.07x | Within |
| 2025-10-16 | After-Close | 5.73% | 9.73% | 1.70x | Exceeded |
| 2026-02-19 | After-Close | 8.37% | 50.55% | 6.04x | Exceeded |
| 2026-05-05 | After-Close | 15.72% | 15.35% | 0.98x | Within |
| 2026-08-05 | After-Close | 16.31% | 14.53% | 0.89x | Within |
| 2026-11-04 | After-Close | 18.20% | 17.08% | 0.94x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
GRAL Options Activity & IV Rank
GRAL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 78.9%
7-DTE IV: 85.3%
Expected Move: $26.90
7-DTE Move: $16.05
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,189
Put Volume: 616
P/C Volume: 0.518
BULLISH
Call OI: 14,508
Put OI: 8,595
P/C OI: 0.592
Total OI: 23,103
ATM Options Pricing
ATM Call: $14.55
ATM Put: $12.35
Call %: 11.0%
Put %: 9.4%
Chain Summary
Chain Volume: 1,805
Chain OI: 23,103
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 4th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
4%
vs own history
GEX tilt
-0.15
OI-weighted, today
Vanna tilt
+0.28
δ-sensitivity to IV
Charm tilt
-0.18
δ-decay vs time
? What is this?
· 36 ATM contracts, 4k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)46.0MediumNov 9
IV Rank (30 DTE)19.7LowNov 9
Straddle Price (30 DTE)$26.90Nov 9
Beta Analysis
Risk Metrics
Beta: 3.0260
Alpha: 68.38%
Correlation: 0.4042
R-Squared: 16.3%
Stock Volatility: 103.2%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 250
Period: 252 trading days
Data Points: 250
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own GRAL
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Rockefeller Capital Management Family office Rockefeller family | $3.9M | #1081 of 4729 | -2.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $628K | #2513 of 3138 | -83.3% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GRAL Institutional Ownership (13F)
Filings for 2026-06-30 · 186 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 39,157,870 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
13 filers$88.95M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $25.40M | 28.55% | 2026-06-30 |
| 2 | IMC-Chicago, LLC Custodian | $21.51M | 24.18% | 2026-09-30 |
| 3 | Citadel Advisors LLC Custodian | $14.62M | 16.43% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $7.99M | 8.98% | 2026-09-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $7.76M | 8.73% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $3.78M | 4.24% | 2026-06-30 |
| 7 | Centiva Capital, LP | $3.41M | 3.84% | 2026-06-30 |
| 8 | BNP Paribas Financial Markets Custodian | $3.07M | 3.45% | 2026-06-30 |
| 9 | UBS Group AG Custodian | $771.45K | 0.87% | 2026-06-30 |
| 10 | D. E. Shaw & Co., Inc. Custodian | $232.12K | 0.26% | 2026-06-30 |
| 11 | Walleye Capital LLC | $225.29K | 0.25% | 2026-06-30 |
| 12 | Walleye Trading LLC | $191.16K | 0.21% | 2026-06-30 |
| 13 | Raiffeisen Bank International AG | $2.73K | <0.01% | 2026-09-30 |
12 filers$170.28M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jefferies Financial Group Inc. | $91.08M | 53.49% | 2026-09-30 |
| 2 | IMC-Chicago, LLC Custodian | $25.60M | 15.03% | 2026-09-30 |
| 3 | Susquehanna International Group, LLP Custodian | $24.56M | 14.43% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $12.85M | 7.55% | 2026-09-30 |
| 5 | Citadel Advisors LLC Custodian | $4.60M | 2.70% | 2026-06-30 |
| 6 | Parkman Healthcare Partners LLC | $3.14M | 1.84% | 2026-06-30 |
| 7 | D. E. Shaw & Co., Inc. Custodian | $3.07M | 1.80% | 2026-06-30 |
| 8 | BNP Paribas Financial Markets Custodian | $2.25M | 1.32% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $1.81M | 1.06% | 2026-06-30 |
| 10 | Jane Street Group, LLC Custodian | $955.78K | 0.56% | 2026-06-30 |
| 11 | TUDOR INVESTMENT CORP ET AL | $266.25K | 0.16% | 2026-06-30 |
| 12 | Walleye Capital LLC | $88.75K | 0.05% | 2026-06-30 |
GRAL Insider Trading (Form 4)
Latest: 2026-10-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Gregory L Summe | Director | Award (A) | +237 | $135.46 | $32.1K | EDGAR |
| 2026-10-16 | Steven Mizell | Director | Award (A) | +148 | $135.46 | $20.0K | EDGAR |
| 2026-10-16 | William J Chase | Director | Award (A) | +153 | $135.46 | $20.7K | EDGAR |
| 2026-10-16 | Joshua J. Ofman | Chief Executive Officer | Sell (S) | −20,000 | $136.85 | -$2.74M | EDGAR |
| 2026-10-07 | Aaron Freidin | Chief Financial Officer | Sell (S) | −23,619 | $146.39 | -$3.46M | EDGAR |
| 2026-10-07 | Andrew John Partridge | Chief Growth Officer | Sell (S) | −7,873 | $146.39 | -$1.15M | EDGAR |
| 2026-09-23 | Joshua J. Ofman | Chief Executive Officer | Mixed Sell −61,452 · Exer +26,452 |
−35,000 | $72.54 | -$5.64M | EDGAR |
| 2026-09-23 | Aaron Freidin | Chief Financial Officer | Sell (S) | −4,100 | $93.34 | -$382.7K | EDGAR |
| 2026-08-31 | Aaron Freidin | Chief Financial Officer | Sell (S) | −7,900 | $85.01 | -$671.6K | EDGAR |
| 2026-08-31 | Joshua J. Ofman | Chief Executive Officer | Sell (S) | −5,000 | $85.02 | -$425.1K | EDGAR |
| 2026-07-16 | Gregory L Summe | Director | Award (A) | +427 | $74.36 | $31.8K | EDGAR |
| 2026-07-16 | William J Chase | Director | Award (A) | +276 | $74.36 | $20.5K | EDGAR |
| 2026-07-16 | Steven Mizell | Director | Award (A) | +268 | $74.36 | $19.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
GRAL Insider Holdings
6 insiders · @ $130.76
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joshua J. Ofman | Chief Executive Officer | 342,271 | $44.76M | -$9.17M | 3 | 2026-10-16 |
| 2 | Aaron Freidin | Chief Financial Officer | 225,364 | $29.47M | -$4.51M | 3 | 2026-10-07 |
| 3 | Andrew John Partridge | Chief Growth Officer | 155,865 | $20.38M | -$1.15M | 1 | 2026-10-07 |
| 4 | Gregory L Summe | Director | 45,909 | $6.00M | $0 | 2 | 2026-10-16 |
| 5 | William J Chase | Director | 43,131 | $5.64M | $0 | 2 | 2026-10-16 |
| 6 | Steven Mizell | Director | 42,978 | $5.62M | $0 | 2 | 2026-10-16 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
GRAL Board & Officers
As of SEC filings through Oct 16, 2026Directors 5
- Gregory L Summe · since Jun 21, 2024
- Steven Mizell · since Jun 21, 2024
- Sarah Krevans · since Oct 21, 2024
- Robert P Ragusa · listed since Mar 2025
- Joshua J. Ofman · listed since Apr 2026
Officers 3
- Joshua J. Ofman · Chief Executive Officer · listed since Jun 2026
- Aaron Freidin · Chief Financial Officer · since Jun 3, 2024
- Andrew John Partridge · Chief Growth Officer · since Jun 1, 2026
Changes in the last 10 years (20)
| Jun 3, 2026 | Joshua J. Ofman listed as Chief Executive Officer (previously President) in SEC filings |
| Jun 1, 2026 | Andrew John Partridge became Chief Growth Officer |
| Apr 9, 2026 | Joshua J. Ofman first listed as a director in an SEC filing |
| Nov 18, 2025 | Illumina, Inc. reported in an SEC filing no longer being a 10% owner |
| Jul 3, 2025 | Chun R Ding reported in an SEC filing no longer being a 10% owner |
| Mar 6, 2025 | Robert P Ragusa first listed as a director in an SEC filing |
| Oct 21, 2024 | Sarah Krevans became a director |
| Sep 26, 2024 | Chun R Ding became a 10% owner |
| Jun 21, 2024 | The company announced the departure of William J Chase from the board in an SEC filing |
| Jun 21, 2024 | The company announced the departure of Charles Dadswell from the board in an SEC filing |
| Jun 21, 2024 | The company announced the departure of Ankur Dhingra from the board in an SEC filing |
| Jun 21, 2024 | Steven Mizell became a director |
| Jun 21, 2024 | Gregory L Summe became a director |
| Jun 11, 2024 | William J Chase became a director |
| Jun 11, 2024 | Charles Dadswell became a director |
| Jun 11, 2024 | Ankur Dhingra became a director |
| Jun 3, 2024 | Robert P Ragusa became Chief Executive Officer |
| Jun 3, 2024 | Joshua J. Ofman became President |
| Jun 3, 2024 | Illumina, Inc. became a 10% owner |
| Jun 3, 2024 | Aaron Freidin became Chief Financial Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
GRAL Proposed Insider Sales (Form 144)
Latest: 2026-10-15
? Form 144 Guide
Last 30d:
1 filing
· $698K notice value
· Last 90d:
6 filings
· $12.8M notice value
· 3 unique filers
· 67% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 | JOSHUA OFMAN | Director, Officer | 5,000 | $698.5K | 2026-10-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-05 | Andrew Partridge | Officer | 7,873 | $1.15M | 2026-10-05 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
| 2026-10-05 | Aaron Freidin | Officer | 23,619 | $3.46M | 2026-10-05 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
| 2026-09-21 | JOSHUA OFMAN | Director, Officer | 71,452 | $5.77M | 2026-09-21 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-27 | JOSHUA OFMAN | Director, Officer | 10,000 | $795.9K | 2026-08-27 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-27 | AARON FREIDIN | Officer | 12,000 | $955.1K | 2026-08-27 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-03 | Andrew Partridge | Officer | 1,705 | $104.2K | 2026-06-03 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
| 2026-04-06 | Aaron Freidin | Officer | 49,414 | $2.56M | 2026-04-03 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
| 2026-04-06 | Joshua Ofman | Officer, Director | 66,522 | $3.44M | 2026-04-06 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
| 2026-04-06 | Robert Ragusa | Officer, Director | 133,230 | $6.89M | 2026-04-06 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
76 ETFs hold GRAL
25 shown · $777.22M total exposure · 0.17% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $182.5M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.17% | $130.2M | $76.6B | 2026-11-06 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.20% | $120.7M | $10.0B | 2026-11-05 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.08% | $70.5M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.34% | $47.5M | $13.9B | 2026-11-06 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.35% | $38.6M | $11.1B | 2026-11-06 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.19% | $33.6M | — | 2026-09-30 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.10% | $33.2M | — | 2026-11-05 |
| 9 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.02% | $16.4M | — | 2026-11-05 |
| 10 | VHT Vanguard Health Care ETF | Vanguard | 0.07% | $16.3M | — | 2026-09-30 |
| 11 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $12.4M | — | 2026-08-31 |
| 12 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.17% | $11.4M | $6.6B | 2026-11-05 |
| 13 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.29% | $9.1M | $3.2B | 2026-11-05 |
| 14 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.11% | $8.1M | — | 2026-11-05 |
| 15 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $7.4M | $93.2B | 2026-11-06 |
| 16 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.22% | $6.0M | — | 2026-07-31 |
| 17 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.46% | $6.0M | $1.3B | 2026-11-06 |
| 18 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.39% | $5.3M | — | 2026-09-30 |
| 19 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.84% | $4.3M | — | 2026-11-06 |
| 20 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $3.9M | — | 2026-11-05 |
| 21 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.22% | $2.9M | $1.4B | 2026-11-06 |
| 22 | PSC Principal U.S. Small-Cap ETF | Nport | 0.12% | $2.8M | — | 2026-06-30 |
| 23 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.04% | $2.7M | — | 2026-11-05 |
| 24 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.06% | $2.6M | $4.2B | 2026-11-06 |
| 25 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.09% | $2.5M | $2.7B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-9.69
TTM Revenue
$165.26M
TTM Net Income
$-391.59M
TTM Op. Cash Flow
$-294.75M
Quarterly figures (9 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $44.69M | $-110.25M | $-2.56 | $-80.73M |
| Q1 '26 | 2026-03-31 | $40.78M | $-93.19M | $-2.29 | $-86.99M |
| Q4 '25 | 2025-12-31 | $43.60M | $-99.18M | $-2.38 | $-63.78M |
| Q3 '25 | 2025-09-30 | $36.19M | $-88.98M | $-2.46 | $-63.24M |
| Q2 '25 | 2025-06-30 | $35.54M | $-113.98M | $-3.18 | $-76.97M |
| Q1 '25 | 2025-03-31 | $31.84M | $-106.21M | $-3.10 | $-95.01M |
| Q4 '24 | 2024-12-31 | $38.25M | $-97.07M | $-1.93 | $-93.49M |
| Q3 '24 | 2024-09-30 | $28.65M | $-125.69M | $-3.94 | $-104.58M |
| Q2 '24 | 2024-06-30 | $31.97M | $-1.59B | $-51.06 | $-171.80M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.01
P/S
30.86
EV/EBITDA
—
EV/Sales
30.52
ROE
-15.4%
ROA
-13.8%
Div Yield
0.00%
FCF Yield
-5.78%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$5.10B
as of 2026-11-09
GRAL vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ISRG Intuitive Surgical Inc. | $160.0B | 55.8 | +20.5% | −17.9% | 18 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.5 | +10.5% | +21.9% | 63 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.0% | 51 |
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +40.0% | 43 |
| GH Guardant Health, Inc. Common Stock | $20.4B | — | +42.7% | +58.3% | 25 |
| TWST Twist Bioscience Corporation Common Stoc | $8.0B | — | +17.8% | +324.1% | 94 |
| GRAL GRAIL, Inc. Common Stock | $5.5B | — | +23.1% | +47.1% | 20 |
| ADPT Adaptive Biotechnologies Corporation Com | $4.5B | — | +50.1% | +92.7% | 51 |
| CDNA CareDx, Inc. | $4.1B | 35.6 | +38.9% | +345.0% | 36 |
| Peer median | $32.7B | 35.6 | +28.6% | +75.5% | 47 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
8.17M
SI % of Float
19.27%
Days to Cover
8.01
Short Vol Ratio
71.5%
Free Float
42.42M
Float %
95.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24